scispace - formally typeset
Journal ArticleDOI

Prolonged n‐3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non‐alcoholic fatty liver disease: a pilot study

Reads0
Chats0
TLDR
This data indicates that n‐3 long‐chain polyunsaturated fatty acids (n‐3 PUFA) as peroxisome proliferator‐activated receptor‐α ligands in improving non‐alcoholic fatty liver disease (NAFLD) in rodents is feasible in humans, although data in humans is still lacking.
Abstract
SUMMARY Background Recent studies suggest a role of n-3 long-chain polyunsaturated fatty acids (n-3 PUFA) as peroxisome proliferator-activated receptor-a ligands in improving non-alcoholic fatty liver disease (NAFLD) in rodents. However, data in humans are still lacking. Aim

read more

Citations
More filters
Journal ArticleDOI

A position statement on NAFLD/NASH based on the EASL 2009 special conference ☆

TL;DR: This poster presents a meta-modelling procedure called “spot-spot analysis” that allows for the direct comparison of the response of the immune system to various types of carbohydrates and its role in disease.
References
More filters
Journal ArticleDOI

Nonalcoholic fatty liver disease.

TL;DR: Nonalcoholic fatty liver disease is associated with an increased risk of all-cause death, probably because of complications of insulin resistance such as vascular disease, as well as due to cirrhosis and hepatocellular carcinoma, which occurs in a minority of patients.
Journal Article

Nonalcoholic fatty liver disease.

Journal ArticleDOI

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

TL;DR: There are no systems for grading necroinflammatory activity or for staging fibrosis as exist for various other forms of chronic liver disease and this study proposes a grading and staging system that reflects the unique histological features of nonalcoholic steatohepatitis.
Journal ArticleDOI

From the authors

TL;DR: Findings, i.e. that as-needed AO provided for a period of 3 months had no effect on quality of life and walked distance, are against the stream of current guidelines.
Journal ArticleDOI

Nonalcoholic fatty liver disease a feature of the metabolic syndrome

TL;DR: It is concluded that NAFLD, in the presence of normoglycemia and normal or moderately increased body weight, is characterized by clinical and laboratory data similar to those found in diabetes and obesity.
Related Papers (5)